P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

• Isha Mol,
• Yannan Hu,
• Joseph Cappelleri,
• Haitao Chu,
• Didem Aydin,
• Patrick Hlavacek

Affiliations

Isha Mol

1 Cytel, RWA - Health Economics, Rotterdam, The Netherlands

Yannan Hu

1 Cytel, RWA - Health Economics, Rotterdam, The Netherlands

Joseph Cappelleri

2 Pfizer Inc, Gronton CT, United States

Haitao Chu

3 Pfizer Inc, New York, United States

Didem Aydin

3 Pfizer Inc, New York, United States

Patrick Hlavacek

3 Pfizer Inc, New York, United States